A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma

2006 ◽  
Vol 65 (1) ◽  
pp. 274-283 ◽  
Author(s):  
Michael W. Brown ◽  
Holly Ning ◽  
Barbara Arora ◽  
Paul S. Albert ◽  
Matthew Poggi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pancreatic Carcinoma ◽  
Dose Escalation ◽  
Locally Advanced ◽  
Intensity Modulated Radiation Therapy ◽  
Intensity Modulated ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma ◽  
Dosimetric Analysis

scholarly journals Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Takahiro Iwai ◽  
Michio Yoshimura ◽  
Ryo Ashida ◽  
Yoko Goto ◽  
Takahiro Kishi ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Pancreatic Carcinoma ◽  
Locally Advanced ◽  
Intensity Modulated Radiotherapy ◽  
Progression Free Survival ◽  
Severe Toxicity ◽  
Free Survival ◽  
Intensity Modulated ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma

Abstract Background It is important to understand how elderly patients with locally advanced pancreatic carcinoma (LAPC) should be treated, since the number of elderly cancer patients will increase. However, the optimal treatment for elderly patients with LAPC remains unclear. The purpose of this study was to evaluate the efficacy and safety of hypofractionated intensity-modulated radiotherapy (IMRT) with concurrent gemcitabine for elderly patients with LAPC. Methods We retrospectively analysed the data from LAPC patients aged ≥ 75 years treated with hypofractionated IMRT (48 Gy in 15 fractions) with concurrent weekly gemcitabine at our institution from February 2013 to December 2018. Overall survival (OS), progression-free survival (PFS), locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and the pattern of recurrence and toxicity were analysed. Results Fifteen patients received treatment during the study period. The median age was 78 years (range 75–86 years), and the Eastern Cooperative Oncology Group (ECOG) performance status (PS) of all patients was 0–1. The median survival time (MST) and median PFS were 20.4 [95% confidence interval (CI) 10.3–36.8] and 13.5 (95% CI 6.4–20.3) months, respectively, and the 1-year OS and PFS rates were 80.0% (95% CI 50–93.1%) and 66.7% (95% CI 37.5–84.6%), respectively. The median LRPFS and median DMFS were 15.6 (95% CI 6.4–36.8) and 14.9 (95% CI 7.0–20.5) months, respectively, and the 1-year LRPFS and DMFS rates were 73.3% (95% CI 43.6–89.1%) and 66.7% (95% CI 37.5–84.6%), respectively. Non-haematologic grade 3 toxicity was observed in three cases, of which only one was induced by radiotherapy, whereas grade 4–5 non-haematologic acute or late toxicities were not observed. Conclusions The OS and PFS of elderly patients with LAPC treated using hypofractionated IMRT with concurrent gemcitabine were favourable and without the occurrence of severe toxicity. This treatment strategy is feasible and promising for elderly LAPC patients with good PS.

Postoperative Gemcitabine Alone and Concurrent with Radiation Therapy in Locally Advanced Pancreatic Carcinoma

2010 ◽  
Vol 96 (4) ◽  
pp. 560-567 ◽  
Author(s):  
Serdar Ozkok ◽  
Senem Demirci ◽  
Deniz Yalman ◽  
Murat Zeytunlu ◽  
Deniz Nart ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pancreatic Carcinoma ◽  
Locally Advanced ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma
Sign in / Sign up

Export Citation Format

Share Document